bioAffinity Technologies Names J. Michael Edwards as Chief …
4 days ago · SAN ANTONIO, October 10, 2024--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early ...
bioAffinity Technologies Reports 217% Sales Growth in Second …
SAN ANTONIO, July 09, 2024 -- (BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...
bioAffinity Technologies News Update - Yahoo Finance
May 2, 2024 · bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. The Company’s first product ...
bioAffinity Technologies News Update
Feb 21, 2024 | Press Releases. SAN ANTONIO, Texas (Feb. 21, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
News & Articles - bioAffinity Tech
News. Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis.
bioAffinity Technologies News Update
May 2, 2024 · bioAffinity Technologies News Update. SAN ANTONIO, Texas (May 2, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) shares recent Company news. CyPath® Lung Sales Ramp Up Month over Month.
bioAffinity Technologies Names J. Michael Edwards as
5 days ago · bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael ...
bioAffinity Technologies News Update
May 2, 2024 · SAN ANTONIO-- (BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news. CyPath® Lung Sales Ramp Up Month over Month. Sales of CyPath ® Lung, our noninvasive diagnostic test for the early detection of lung cancer, continue to climb, with April sales up 21% over March.
Lung cancer test speeds growth of San Antonio's bioAffinity
2 days ago · FROM 2017: BioAffinity raises $4 million as lung cancer test nears market. “After the sample runs through the flow, which takes about half hour, the data goes into this algorithm and out comes ...
bioAffinity Technologies, Inc. (BIAF)
Jun 20, 2024 · Oct 9, 2024. bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test. Sep 18, 2024. Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis. Aug 23, 2024.